Has the U.K. Pharma Industry valuation changed over the past few years?

Investors are pessimistic on the British Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically. The industry is trading at a PE ratio of 19.9x which is lower than its 3-year average PE of 25.2x. The industry is trading close to its 3-year average PS ratio of 3.4x.

Which industries have driven the changes within the U.K. Healthcare industry?

There are no additional sub-industries under this industry.

U.K. (FTSE) Pharma Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Sat, 20 Jun 2026	UK£316.9b	UK£92.7b	UK£15.9b	17.7x	19.9x	3.4x
Mon, 18 May 2026	UK£321.0b	UK£92.4b	UK£15.9b	17.7x	20.2x	3.5x
Wed, 15 Apr 2026	UK£356.5b	UK£90.1b	UK£15.5b	19.1x	23x	4x
Fri, 13 Mar 2026	UK£342.2b	UK£90.8b	UK£15.7b	21.1x	21.8x	3.8x
Sun, 08 Feb 2026	UK£348.0b	UK£89.3b	UK£14.7b	24x	23.6x	3.9x
Tue, 06 Jan 2026	UK£319.2b	UK£89.2b	UK£14.6b	21.8x	21.9x	3.6x
Thu, 04 Dec 2025	UK£323.8b	UK£89.8b	UK£14.7b	21.1x	22.1x	3.6x
Sat, 01 Nov 2025	UK£302.8b	UK£89.3b	UK£13.9b	20.7x	21.7x	3.4x
Mon, 29 Sep 2025	UK£265.8b	UK£87.8b	UK£11.7b	18.4x	22.6x	3x
Wed, 27 Aug 2025	UK£281.7b	UK£87.6b	UK£11.7b	21.7x	24.1x	3.2x
Fri, 25 Jul 2025	UK£265.2b	UK£86.4b	UK£10.6b	30.1x	25x	3.1x
Sun, 22 Jun 2025	UK£259.3b	UK£86.6b	UK£10.6b	25.9x	24.4x	3x
Tue, 20 May 2025	UK£260.7b	UK£86.9b	UK£10.7b	26.5x	24.4x	3x
Thu, 17 Apr 2025	UK£254.7b	UK£86.6b	UK£9.6b	26.9x	26.5x	2.9x
Sat, 15 Mar 2025	UK£290.1b	UK£87.7b	UK£9.6b	28.8x	30.2x	3.3x
Mon, 10 Feb 2025	UK£280.9b	UK£89.5b	UK£9.5b	30.1x	29.4x	3.1x
Wed, 08 Jan 2025	UK£228.3b	UK£75.6b	UK£7.8b	31.8x	29.3x	3x
Fri, 06 Dec 2024	UK£226.8b	UK£74.7b	UK£7.7b	32.1x	29.5x	3x
Sun, 03 Nov 2024	UK£236.3b	UK£72.6b	UK£7.6b	31.1x	31.2x	3.3x
Tue, 01 Oct 2024	UK£249.2b	UK£71.3b	UK£8.9b	30.4x	27.9x	3.5x
Thu, 29 Aug 2024	UK£279.6b	UK£71.9b	UK£9.0b	41.9x	31.2x	3.9x
Sat, 27 Jul 2024	UK£259.8b	UK£72.2b	UK£9.6b	34.8x	27.2x	3.6x
Mon, 24 Jun 2024	UK£266.4b	UK£71.7b	UK£9.6b	30.2x	27.8x	3.7x
Wed, 22 May 2024	UK£271.2b	UK£71.5b	UK£9.6b	33.9x	28.3x	3.8x
Fri, 19 Apr 2024	UK£243.1b	UK£71.4b	UK£9.8b	31.9x	24.9x	3.4x
Sun, 17 Mar 2024	UK£236.0b	UK£70.4b	UK£9.7b	32.3x	24.3x	3.4x
Tue, 13 Feb 2024	UK£220.4b	UK£69.7b	UK£9.6b	34.4x	22.9x	3.2x
Thu, 11 Jan 2024	UK£244.6b	UK£68.8b	UK£10.7b	36.5x	22.9x	3.6x
Sat, 09 Dec 2023	UK£226.9b	UK£69.4b	UK£10.7b	33.4x	21.1x	3.3x
Mon, 06 Nov 2023	UK£229.8b	UK£70.3b	UK£11.0b	53x	20.9x	3.3x
Wed, 04 Oct 2023	UK£244.4b	UK£70.9b	UK£10.5b	76.3x	23.4x	3.4x
Fri, 01 Sep 2023	UK£236.3b	UK£69.1b	UK£10.2b	53.5x	23.2x	3.4x
Sun, 30 Jul 2023	UK£241.7b	UK£68.1b	UK£9.9b	52.3x	24.5x	3.5x
Tue, 27 Jun 2023	UK£245.7b	UK£67.8b	UK£7.9b	55.5x	31.2x	3.6x


GB Market	-1.30%
Healthcare	-1.79%
Pharma	-1.95%
Pharma	-1.95%

	Company	Last Price	7D	1Y	Valuation
No data available

Announcement • Jun 12

Hutchmed China Limited Highlights Sovleplenib Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia

Hutchmed China Limited announced results from the Phase III part of the ESLIM-02 study of sovleplenib in patients with warm antibody autoimmune hemolytic anemia (wAIHA) in China were presented on June 11, 2026 during the European Hematology Association (EHA) Congress in Stockholm, Sweden. Supported by data from the ESLIM-02 study, a New Drug Application (NDA) for sovleplenib for the treatment of adult patients with wAIHA who have had an insufficient response to at least one previous glucocorticoid treatment has been accepted for review and granted priority review by the China National Medical Products Administration (NMPA) in April 2026. The NMPA granted Breakthrough Therapy Designation to sovleplenib for the treatment of wAIHA in March 2026. The ESLIM-02 presentation was selected for the official EHA Press Program. ESLIM-02 is a randomized, double blind, placebo-controlled China Phase II/III study in adult patients with primary or secondary wAIHA who had relapsed or were refractory to at least one prior line of standard treatment (NCT05535933). Results from the Phase II part of the study were published in The Lancet Haematology in January 2025. In Phase III part of the study, 90 patients were randomized 1:1 to receive either sovleplenib (n=44) or placebo (n=46) at a dose of 300 mg once daily for 24 weeks. The study met its primary endpoint, with sovleplenib demonstrating a significantly higher durable response rate during weeks 5-24 compared to placebo (66% vs 15%, p<0.0001). During the 24-week double-blind treatment period, sovleplenib demonstrated superior efficacy across several key metrics; specifically, the overall response rate-defined as hemoglobin (Hb) =100 g/L with an increase of =20 g/L from baseline without rescue therapy-was significantly increased (70% vs 22%, p<0.0001). The use of protocol-defined rescue therapy was significantly reduced with sovleplenib (16% vs 54%, p=0.0001), fewer patients received red blood cell transfusion (11% vs 43%) and higher patients with tapering or discontinuation of glucocorticoids or other baseline concomitant anti-wAIHA therapies (50% vs 15%, p=0.003). Median time to response was 3.1 weeks for sovleplenib versus 6.3 weeks for placebo, while the median cumulative duration of response among overall responders was 16.1 versus 6.1 weeks, respectively. Additionally, an improvement in hemolytic markers was observed with sovleplenib compared with placebo, showing an alleviation of active hemolysis. These efficacy findings remained consistent across all sensitivity analyses, and all subgroup analyses further supported the primary endpoint results. Notably, in patients who had received prior rituximab therapy, the durable response rate continued to favor sovleplenib over placebo (69% vs 16%, p=0.0022). Sovleplenib demonstrated a favorable safety profile. Grade =3 treatment-emergent adverse events (TEAE) were reported in 43% patients in the sovleplenib arm and 59% patients in the placebo arm. The most common Grade =3 TEAEs, occurring in at least 10% of patients, were warm autoimmune hemolytic anemia (18% vs 43%) and upper respiratory tract infection (2% vs 11%). There were no TEAE-related deaths or treatment discontinuations reported in the sovleplenib group. Sovleplenib is a novel, investigational, selective small molecule inhibitor for oral administration targeting Syk. Syk is a major component in B-cell receptor and Fc receptor signaling and is an established target for the treatment of multiple subtypes of B-cell lymphomas and autoimmune disorders. The accelerated clearance of antibody-coated RBCs by immunoglobulin Fc-gamma receptor (Fc?R) bearing macrophages is thought to be the pathogenic mechanism in wAIHA. Activated Syk mediates downstream signaling of the activated Fc receptors in phagocytic cells, resulting in phagocytosis of RBCs. In addition, activation of Syk through the B-cell receptor mediates activation and differentiation of B-lymphocytes into antibody secreting plasma cells. Inhibition of Syk may have potential effects in the treatment of wAIHA through inhibition of phagocytosis and reduction of antibody production. In addition to wAIHA, sovleplenib is also being studied in immune thrombocytopenia (ITP). Positive results from ESLIM-01 (NCT05029635), a Phase III trial in China of sovleplenib in patients with primary ITP, have been published in The Lancet Haematology. The NMPA accepted for review the resubmitted NDA filing for the treatment of ITP and granted it priority review in February 2026. According to IQVIA, China has 430,000 existing patients with 41,000 new ITP patients each year. About half of ITP patients fail to have satisfactory results from currently approved treatments such as TPO (thrombopoietin) /TPO-RAs (thrombopoietin receptor agonists). HUTCHMED currently retains all rights to sovleplenib worldwide.

Announcement • Jun 12

Allergy Therapeutics plc Presents Data From Pollen And Food Allergy Research Portfolio And Hosts Symposium At EAACI Congress 2026

Allergy Therapeutics plc announced that it will be presenting data from across its pollen and food allergy research portfolio at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2026, taking place in Istanbul, Türkiye, from 12 June 2026 through to 15 June 2026. Allergy Therapeutics will present 15 posters and oral presentations at the conference, including: Data from the Group's Phase I/IIa PROTECT trial of VLP Peanut, the Group's innovative, short-course peanut allergy immunotherapy candidate. The PROTECT trial met the primary endpoint, demonstrating a benign safety profile of VLP Peanut, with a strong dose-response in immunomodulating tolerogenic immune responses induced confirming clinical proof of concept. Blinded safety data from the first year of the Company's G308 Phase III trial evaluating the short- and long-term efficacy and safety of Grass MATA MPL in a paediatric population with grass-induced seasonal allergic rhinitis and rhinoconjunctivitis, demonstrating a benign safety profile in the first year of treatment and a low trial discontinuation rate. The Company will also host a symposium at the EAACI Congress from 15:00-16:00 TRT, co-chaired by Dr. Mohamed Shamji, Professor of Immunology and Allergy at Imperial College London, and Dr. Janice Layhadi, Research Associate at the Immunomodulation and Tolerance Group of Allergy & Clinical Immunology, Imperial College London. The symposium, titled Scoring Against Allergies: New Therapeutic Strategies on the Horizon, will focus on Allergy Therapeutics' ongoing work with Grass MATA MPL in a paediatric population and highlight the Company's progression of VLP Peanut as a novel therapeutic candidate for peanut allergy. In addition, the EAACI Early Career Research Award, supported by Allergy Therapeutics, will be presented to this year's recipient, Juan Luis Paris, PhD, at this year's congress. Juan Luis is a Principal Investigator at the Instituto de Investigación Biomédica de Málaga (IBIMA, Málaga, Spain), where his research is focused on developing bio- and nano-materials for therapeutic immunomodulation in allergic diseases and other pathologies. The EAACI Early Career Research Award provides an unrestricted research grant of up to EUR 30,000 and is open to EAACI Junior Members who have previously published their high-impact research on allergy and immunology and demonstrated their drive and dedication in the area of immunotherapy. Data from the Phase I/IIa PROTECT trial of VLP Peanut have confirmed a strong safety and tolerability profile of this novel immunotherapy candidate while also demonstrating clinical proof of concept, and preparations for the Group's Phase IIb trial are continuing. Clinical progress with Grass MATA MPL has continued following regulatory approval of the product in Germany, with encouraging paediatric safety data strengthening the evidence base that the product could provide a differentiated treatment option for grass-induced seasonal allergic rhinitis and rhinoconjunctivitis in a younger patient population. The complete list of Allergy Therapeutics-sponsored abstracts accepted by EAACI for presentation are available on the Group's website. No new material price sensitive information will be disclosed on Allergy Therapeutics at the EAACI Congress 2026.

U.K. (FTSE) Pharma Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

AstraZeneca (LSE:AZN) Stock Could Be 20.2% Below Fair Value After Recent Pullback

GSK Stock Draws Interest After FDA Approval of First Oral cUTI Antibiotic Utebzi

HIK: Manufacturing Expansion And Steady Outlook Will Support Future Re Rating

HLN: Cautious Ratings And Execution Progress Will Guide Future Share Price

Hutchmed China Limited Highlights Sovleplenib Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia

Allergy Therapeutics plc Presents Data From Pollen And Food Allergy Research Portfolio And Hosts Symposium At EAACI Congress 2026

ImmuPharma plc, Annual General Meeting, Jun 25, 2026

New major risk - Financial position